Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Garrett

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|January 15, 2022
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennialAlan J Korman, Sarah C Garrett-Thomson, Nils Lonberg
Nature Reviews. Drug Discovery|December 23, 2021
The foundations of immune checkpoint blockade and the ipilimumab approval decennialAlan J Korman, Sarah C Garrett-Thomson, Nils Lonberg
Structure (London, England : 1993)|April 2, 2019
Computational Redesign of PD-1 Interface for PD-L1 Ligand SelectivityRojan Shrestha, Sarah C Garrett, Steven C Almo, et al.
The Journal of Biological Chemistry|October 26, 2005
S100A4, a mediator of metastasisSarah C Garrett, Kristen M Varney, David J Weber, et al.
Structure (London, England : 1993)|August 16, 2020
Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160Rojan Shrestha, Sarah C Garrett-Thomson, Weifeng Liu, et al.
Biochemistry|December 25, 2007
A biosensor of S100A4 metastasis factor activation: inhibitor screening and cellular activation dynamicsSarah C Garrett, Louis Hodgson, Andrew Rybin, et al.
Structure (London, England : 1993)|June 25, 2019
Structural Basis of CD160:HVEM RecognitionWeifeng Liu, Sarah C Garrett, Elena V Fedorov, et al.
Biochemistry|April 16, 2008
Structure of Ca2+-bound S100A4 and its interaction with peptides derived from nonmuscle myosin-IIAVladimir N Malashkevich, Kristen M Varney, Sarah C Garrett, et al.
Plos One|June 5, 2020
Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complexSarah C Garrett-Thomson, Aldo Massimi, Elena V Fedorov, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2017
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumabUdupi A Ramagopal, Weifeng Liu, Sarah C Garrett-Thomson, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|January 15, 2022
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennialAlan J Korman, Sarah C Garrett-Thomson, Nils Lonberg
Nature Reviews. Drug Discovery|December 23, 2021
The foundations of immune checkpoint blockade and the ipilimumab approval decennialAlan J Korman, Sarah C Garrett-Thomson, Nils Lonberg
Structure (London, England : 1993)|April 2, 2019
Computational Redesign of PD-1 Interface for PD-L1 Ligand SelectivityRojan Shrestha, Sarah C Garrett, Steven C Almo, et al.
The Journal of Biological Chemistry|October 26, 2005
S100A4, a mediator of metastasisSarah C Garrett, Kristen M Varney, David J Weber, et al.
Structure (London, England : 1993)|August 16, 2020
Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160Rojan Shrestha, Sarah C Garrett-Thomson, Weifeng Liu, et al.
Biochemistry|December 25, 2007
A biosensor of S100A4 metastasis factor activation: inhibitor screening and cellular activation dynamicsSarah C Garrett, Louis Hodgson, Andrew Rybin, et al.
Structure (London, England : 1993)|June 25, 2019
Structural Basis of CD160:HVEM RecognitionWeifeng Liu, Sarah C Garrett, Elena V Fedorov, et al.
Biochemistry|April 16, 2008
Structure of Ca2+-bound S100A4 and its interaction with peptides derived from nonmuscle myosin-IIAVladimir N Malashkevich, Kristen M Varney, Sarah C Garrett, et al.
Plos One|June 5, 2020
Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complexSarah C Garrett-Thomson, Aldo Massimi, Elena V Fedorov, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2017
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumabUdupi A Ramagopal, Weifeng Liu, Sarah C Garrett-Thomson, et al.
Pageof 2